Thalidomide 3845 AT13148 is currently being developed

AT13148 is currently being developed by Astex Pharmaceuticals

3-c]pyrimidin-5-amine

Mol Med Rep

another frequently used cardiac marker gene (NKX2-5) is also significantly increased by this small molecule in C2C12 cells

Solubility: DMSO: 90 mg/mL(201

Thalidomide 3845 AT13148 is currently being developedThalidomide is a synthetic derivative of glutamic acid (alpha phthalimido glutarimide) with teratogenic, immunomodulatory, anti inflammatory and anti angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In